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ABSTRACT 
 
 
In this paper, the distribution and redistribution of the amphetamine derivative, 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) is brought into focus. Animal 
experimental data were compared with internationally reported MDMA-related human 
fatalities: in general, these turned out to be parallel with each other.   
Due to its inherent properties (e.g. significant volume of distribution), MDMA is 
liable to postmortem redistribution.  Indeed, very high concentrations have been found in 
cardiac blood and tissues located centrally in the body (blood-rich organs such as lungs and 
liver in particular).  This confirms that post-mortem redistribution due to diffusion from 
higher to lower concentration can easily take place, mainly at longer post-mortem intervals 
and when putrefaction occurs.  Therefore, we can conclude that for post-mortem 
quantitation of amphetamine and derivatives, and MDMA in particular, peripheral blood 
sampling (e.g. femoral vein) remains compulsory.  However, if the latter is impossible, 
MDMA quantification in a few alternative matrices such as vitreous humour and iliopsoas 
muscle may provide additional information to come to a reliable conclusion.   Furthermore, 
it should be stressed that – at present – it is impossible to estimate the individual 
susceptibility to the various possible adverse effects of MDMA, which implies that it is 
impossible to provide a “safe” or “therapeutic” blood MDMA level. Therefore, in current 
forensic practice, the post-mortem pathological and toxicological findings should form an 
entity in order to draw a well-grounded conclusion. 
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I. Introduction 
 
 The detection of toxic substances, in particular of illicit drugs, plays an important role in the 
forensic inquiry.  It is important to point out whether or not a person was under the influence at the very 
moment of an accident or criminal offence.  
Whereas the blood or plasma level of a substance often correlates with recent cerebral effects in a living 
person, this is not necessarily applicable to the dead due to interfering thanato-chemical processes [1].  
Problems include post-mortem degradation, redistribution and sometimes even post-mortem production of 
a substance.  When drug instability is important, falsely decreased levels may be measured or the drug can 
become undetectable.  On the other hand, post-mortem redistribution and/or neo-formation may result in 
falsely elevated concentrations.  The competition between drug instability and redistribution should be 
taken into account when considering a specific concentration as being therapeutic, toxic or lethal.  These 
post-mortem phenomena have been investigated for several compounds such as ethanol, cocaine, 
benzodiazepines, barbiturates and antidepressant medication.  For ethanol, bacterial post-mortem 
production has been proven [2], whereas for cocaine, instability is prominent [3].  In addition, the 
interpretation of cocaine levels may be difficult due to competing post-mortem processes, namely tissue 
release on the one hand, and chemical and enzymatic degradation of the substance on the other [4,5].  
Some benzodiazepines - and nitrobenzodiazepines in particular - are chemically and metabolically very 
unstable [6].  Post-mortem redistribution into cardiac blood has also been substantiated, for example for 
barbiturates [7], amitriptyline [8-12] and procainamide [13].   In general, basic, highly lipophilic drugs, 
with an important volume of distribution (> 3 l/kg) are likely to undergo post-mortem redistribution [14].  
To a certain extent, the interference of post-mortem phenomena and – more in particular – of post-mortem 
redistribution, can be avoided by sampling blood as soon as possible after death from an isolated 
peripheral vein such as the femoral vein [15]. However, post-mortem diffusion of diphenhydramine and 
dihydrocodeine out of the bladder into femoral blood has been substantiated [16]. 
Particular attention to post-mortem toxicological and analytical aspects is provided in a few reviews [17-
21]. 
In addition,  since vitreous humour – due to its well-isolated position – is only to a minor extent influenced 
by autolytic processes, this specimen can be an interesting alternative for toxicological purposes.  
Moreover, vitreous fluid is simple to sample and not affected by haemolysis.  Vitreous humour levels have 
been studied for various substances such as alcohol [22], morphine [23] and cocaine [24].   
Furthermore, in case of severe decomposition, the use of post-mortem samples for toxicology 
(blood, urine, vitreous humour, and tissues such as liver, kidney) can be seriously hampered.  In these 
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circumstances alternative matrices such as bone marrow or even larvae of insects feeding on the host can 
be useful [25]. 
Moreover, the above-mentioned post-mortem issue interferes with the standard question for all 
substances: is the quantified plasma or blood level within the therapeutic range?  Or can the latter induce a 
toxic state or even death? 
Abuse of amphetamine derivatives such as MDMA and 3,4-methylenedioxy-amphetamine 
(MDA) is an important public issue and fatalities are not infrequent in current forensic practice.  
Furthermore, several authors discuss the troubles encountered in driving under the influence of MDMA 
(e.g. [26]). Since amphetamine-related fatalities, including those of MDMA users, are increasingly 
encountered in medico-legal practice (e.g. [27-33]), fundamental research on these post-mortem 
phenomena remains required.  MDMA is frequently improperly considered as “safe” and providing a 
“safety ratio” [34] is to our opinion hazardous. 
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II. Scope 
This manuscript reviews the current knowledge of possible interference by the above-mentioned 
post-mortem phenomena when interpreting a post-mortem 3,4-methylenedioxymethamphetamine 
(MDMA) blood level.  To this end, animal experimental and human data are discussed with focus on the 
publications referenced in the PubMed and Web of Science databases over the last 10 years.  In addition, 
we provide an overview of the data on the (re)distribution of MDMA, in order to study the relevance of 
sampling post-mortem specimens, additional to blood and urine, such as several tissues (e.g. liver, 
kidneys, muscle, brain), hair, vitreous humour and larvae.  Furthermore, the question was posed as to 
whether the post-mortem phenomena relating to MDMA are in line with those for the other amphetamine 
derivatives. 
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III. Post-mortem phenomena – thanatological changes applied to MDMA 
III.1. Post-mortem degradation  
Post-mortem degradation of drugs can be due to chemical decomposition of labile molecules or be the 
result of metabolic processes [35]. MDMA appears to be stable in vitro [36, 37].  In addition, in humans, 
the metabolism of MDMA to the active metabolite 3,4-methylenedioxyamphetamine (MDA) is only a 
minor pathway;  indeed, formation of the glucuronite or sulfate conjugate metabolites 3,4-
dihydroxymethamphetamine (HHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) is regarded 
as the predominant pathway in the MDMA metabolism [38].  MDA as the active metabolite of MDMA is 
usually encountered approximately at 5-10 % of the corresponding MDMA serum or plasma levels [39, 
40]. Even though MDA is still pharmacologically active, it has thus a less important contribution than 
formerly considered.  
 
III.2. Interference by bacteria 
At present, there are no arguments to sustain the hypothesis that MDMA is metabolized post mortem by 
means of bacteria, in contrast to e.g. nitrobenzodiazepines [41].  However, rabbit experiments indicated 
that MDMA can be converted post mortem to MDA; it is at present not clear how this reaction takes place 
(see below, paragraph III.3.1).  
 
III.3. Post-mortem (re)distribution 
III.3.1. Animal experimental data 
Animal experiments dealing with this issue for amphetamine or its analogues are scarce [42, 43].  
Hilberg et al. described an experiment in which post-mortem redistribution of amphetamine in the rat was 
studied [42], with further extrapolation to a few medico-legal cases [44]. Moriya et al. demonstrated 
redistribution of methamphetamine into cardiac blood via pulmonary blood vessels in the early post-
mortem period [43]. 
In the experimental work featured by a multidisciplinary approach at Ghent University 
(Belgium), the post-mortem problems for MDMA were examined using an experimental rabbit model.  In 
a first study, the value of post-mortem vitreous humour MDMA levels was investigated for the purpose of 
avoiding possible thanato-chemical difficulties such as post-mortem redistribution [45].  First, the 
pharmacokinetics of MDMA in the rabbit after intravenous (iv) administration were considered.  A high 
volume of distribution (5 l/kg), a high systemic clearance (4.1 l/kg per h) and a relatively short half-life (1 
h) were found following iv administration of MDMA.  A distinct relationship between the MDMA 
concentrations in the vascular compartment and the vitreous humour was substantiated.  Equilibration 
between the vascular compartment and the vitreous humour was attained about one hour after intravenous 
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administration.  The ratio of the MDMA concentration in vitreous humour to the MDMA blood level was 
about 1.1 at 120 and 240 minutes after infusion, which indicates a slight accumulation of MDMA in the 
vitreous compartment.  Moreover, a preliminary thanato-toxicological investigation - in which a post-
mortem interval of up to 72 h was considered - demonstrated that MDMA concentrations in cardiac blood 
increased post mortem, whereas vitreous humour MDMA levels were more stable and thus presumably 
more representative of the ante-mortem blood concentration.  
In addition, the post-mortem stability and (re)distribution of MDMA in the rabbit model were 
further investigated in order to determine which body fluid(s) and/or tissue(s) after death most closely 
represent the actual ante-mortem concentration. This second study [46] dealt with the distribution of 
MDMA and its metabolite MDA in different body fluids and tissues of rabbits that were killed 2 hours 
after iv administration of MDMA.  Three groups of rabbits were studied.  In the first group (control 
group), the study was performed immediately after sacrifice and in the second group, the animals were 
preserved at ambient temperature either 24 or 72 h post mortem prior to sampling.  Theoretically, post-
mortem increases in cardiac blood levels can occur due to intravascular diffusion out of blood-rich organs 
such as the liver and the lungs [43].  Therefore, in the third group, ligation of the large vessels around the 
heart was performed (immediately after killing) and these rabbits were further treated as in the second 
group.  In the first group (control group, sampling done immediately after killing) considerable MDMA 
concentrations were found in the brain and in both lungs.  Our data also pointed to substantial elimination 
of MDMA by hepatic biotransformation and excretion via the bile in addition to renal excretion.  In the 
second group (post-mortem interval either 24 or 72 h prior to sampling), an increase of MDMA and MDA 
levels in the liver and the eye globe walls was noted.  In the lungs, on the other hand, levels tended to 
decline as a function of increasing post-mortem interval.  MDMA concentrations in cardiac and iliopsoas 
muscle were fairly comparable, remaining stable up to 72 h after death.  A third group, in which the large 
vessels around the heart were ligated immediately after killing, did not show significant differences in 
blood and tissue MDMA concentrations when compared with the animals of group 2.   Therefore, in the 
rabbit, post-mortem redistribution of MDMA at the cellular level (viz. by pure diffusion gradient from 
higher to lower concentrations) is probably more important than its redistribution via vascular pathways. 
In addition, MDA levels were relatively low in all samples, indicating that this molecule is not a major 
metabolite in the rabbit, at least within the first two hours after administration.  Furthermore, the value of 
vitreous humour as a reliable post-mortem specimen was confirmed. The distribution and redistribution of 
MDMA and MDA in rabbit tissues were in line with the data obtained after administration of 
amphetamine in the rat [42, 47]. 
Since drug levels can be affected by gastric diffusion when the stomach contains a substantial 
amount of the drug or by diffusion from the trachea when agonal aspiration or post-mortem regurgitation 
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of vomit occurs, these phenomena were simulated in another rabbit model (third study [48]).  Indeed, in 
humans, MDMA is mostly taken orally and therefore, drug levels can be affected by agonal vomit 
aspiration or post-mortem regurgitation in the airways when the subject dies shortly after ingestion, and – 
as a result – the distribution is not yet completed.  The influence of the gastric reservoir function [49] and 
vomit aspiration or regurgitation [50] has previously been proven for ethanol. For MDMA, in the third 
rabbit animal model, post-mortem infusion of an MDMA solution was performed either in the trachea or 
in the stomach and the diffusion was studied up to 72 hours after administration [48].  After post-mortem 
tracheal infusion, MDMA easily diffused not only into the lungs but also in large quantities into the 
cardiac blood and – to a lesser extent – into the cardiac muscle. MDMA was also found in the closely 
adjacent diaphragm and in the upper abdominal organs, including the liver and the stomach.  Following 
post-mortem infusion into the stomach, considerable MDMA levels were found in cardiac blood and 
muscle, both lungs, diaphragm and liver tissue, when the solution was concentrated nearby the lower 
oesophageal sphincter.   However, when the MDMA solution was present deeper in the stomach, MDMA 
levels were higher in the spleen and liver and relatively lower in cardiac blood and muscle.  These results 
indicate that the diffusion of MDMA out of the stomach contents or aspirated vomit and particularly 
gastro-oesophageal reflux, can lead to considerable post-mortem redistribution. In both experiments, 
MDA levels were low or below the limit of quantitation in most tissues, but were substantial in cardiac 
blood and muscle, lung and diaphragm, thus indicating that MDMA can be converted into MDA even 
after death.  However, the mechanism for the latter is at present unclear. 
Entomological data dealing with MDMA are scarce.  Goff et al. [51] observed that the period 
required for completion of the larval development in Parasarcophaga ruficornis was significantly shorter 
for the larvae which were fed on liver tissues from rabbits receiving a single MDMA dose of 67 mg 
intravenously and this colony had the lowest total mortality rate during development.  However, no 
significant differences were noticed in the duration of the puparial period.  Therefore, Goff et al. 
concluded that this should be taken into account when determining the post-mortem interval by 
entomological study in MDMA-related fatalities [51]. 
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III.3.2. Human data 
In this section the animal experimental data are compared with the human findings. The focus is on 
MDMA and not on some other amphetamine derivatives. The post-mortem distribution of MDMA (and its 
metabolite MDA) in the human body was investigated, in order to evaluate which fluid and/or tissue 
sampled after death most closely represents the ante-mortem concentration.  Two different – but 
complementary – approaches were examined:  first, the thanato-toxicological approach and second, the 
anatomo-pathological/thanatological approach, with emphasis on immunohistochemistry. 
 
III.3.2.1. Thanato-toxicological data 
Though MDMA appears to be stable in vitro, its post-mortem (re)distribution in the body has barely been 
explored, with the exception of case reports: apart from blood and urine concentrations, only some tissue 
levels have been reported.  An overview of the most relevant post-mortem data found in case reports dealing 
with MDMA-related fatalities are summarized in Supplementary Table 1 [29, 30, 52-95]. Indeed, at present 
the interpretation of a specific post-mortem MDMA blood level should be made in the light of the available 
case reports.  Unfortunately, the blood sampling site is often not mentioned, though when it is available, it is 
indicated. Furthermore, fatalities only providing ante-mortem data (e.g. serum levels) and those in which a 
quantified post-mortem MDMA blood level is not available, are not included in Supplementary Table 1. In 
addition, all other amphetamine-related fatalities are not taken into account unless MDMA was part of the 
quantified toxicological results. 
In particular, attention is paid to available MDMA blood (cardiac or peripheral), urine, gastric contents, 
vitreous humour and tissue levels. For the lungs, preference was given to report the upper lobe MDMA levels 
as in the lower lobes blood stasis is frequent.  Considering tissue levels, those were brought into focus which 
can be compared in several case reports, i.e. mainly liver, kidney, brain, iliopsoas muscle.   
Referring to the available thanato-toxicological literature data (see Supplementary Table 1) – 
indicating a wide range of concentrations –, the interpretation of the MDMA blood level after death 
remains a debatable question.  Indeed a broad range of concentrations is found, viz. between 0.04 µg/ml 
[81] and 84.00 µg/ml [92] in femoral blood. In the latter case, a femoral blood level of 84.00 µg/ml is 
extraordinary as the majority of the blood MDMA levels lies between 0.5 and 4 to 5 µg/ml.  
Unfortunately, the post-mortem interval in that exceptional MDMA fatality is not indicated. 
In this review, concentrations in various fluids (blood sampled at different locations, vitreous 
humour, urine and bile) and tissues such as cardiac muscle, lungs, liver, kidneys, spleen, iliopsoas muscle, 
and brain were closely considered in MDMA overdose victims. These data show that high MDMA 
concentrations can be found in organs such as the brain (i.e. important target organ) [52, 53, 57, 60, 61, 67, 
69, 90] and the liver  [57, 60, 61, 65, 67, 69, 79, 87, 88, 90]. In addition, in the MDMA-related fatalities, 
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very high concentrations were found in cardiac blood and tissues located centrally in the body (blood-rich 
organs such as lungs and liver in particular).  The latter confirms that post-mortem redistribution due to 
diffusion from higher to lower concentration can easily take place, mainly at longer post-mortem intervals 
and when putrefaction occurs.  These findings corroborated the animal experimental data in which post-
mortem redistribution of MDMA into cardiac blood was substantiated [46, 48].  These results are also in 
line with the available literature data for amphetamine (AMP), methamphetamine (METH) and MDA (e.g. 
[15, 44, 96-104] ), which indicated that concentrations in cardiac blood are obviously higher than those in 
peripheral blood.  For example, methamphetamine concentrations measured in the left heart of human 
fatalities are about two times higher than those quantified in the right heart [103].  Blood collected from 
the pulmonary vessels sometimes showed concentrations that were many times higher than blood sampled 
from the heart and, as a result, diffusion out of the lungs into the pulmonary circulation was demonstrated 
[103]. In addition, significant levels of AMP, METH and MDA have been found in several tissues such as 
liver and brain, but also in blood-rich organs such as the lungs, which means that these substances are 
liable to post-mortem redistribution. 
Referring to Supplementary Table 1 and our data [30, 60, 61, 105], it is obvious that a peripheral 
sampling site (such as the femoral vein) is recommended.  Toxicologists should be aware of the blood 
sampling location and whether a peripheral blood sample is available.  They should be cautious in their 
conclusions as to whether or not the quantified level is either toxic or lethal.   When peripheral blood 
samples are not available (due to severe loss of blood, such as in polytrauma), iliopsoas-muscle and 
vitreous humour could be valuable alternatives. In humans, quantification of 3,4-
methylenedioxymethamphetamine (MDMA, “ecstasy”) in the vitreous humour has only been performed in 
a few cases [56, 57, 59-61, 64, 69, 82].   However, when advanced putrefaction has occurred, vitreous 
humour is often no longer available due to dehydration, and iliopsoas muscle levels should be interpreted 
with caution (see e.g. case 01/158 in [61]: the iliopsoas muscle value was obviously higher than the 
femoral blood level).  In contrast to the rabbit experiments, there are arguments for a direct transvascular 
redistribution, for example, from the lungs to the cardiac chambers in humans.  Moreover, due to the post-
mortem processes, the toxicological and autopsy findings should be considered as a whole when drawing 
the medico-legal conclusions.  
MDMA (and MDA) quantification in hair samples are at present rare [52, 70, 90] (see 
Supplementary Table 1).  In addition, these can be an indication of previous use and thus tolerance.  
Further investigation is necessary to determine whether these analyses can be interesting, e.g. in case of 
suspicion of an anaphylactic reaction or in the interpretation of a quantified MDMA level in a supposedly 
regular user.  
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III.3.2.2. Anatomo-pathological/thanatological approach, with emphasis on immunohistochemistry.   
In most drug-related immunohistochemical studies, the drug-effects are indirectly studied, e.g. by 
demonstration of rhabdomyolysis [67, 68, 106]. In this review, we will focus on the (re)distribution of 
MDMA itself and thus in this section, a semi-quantitative visual presentation of the distribution of MDMA 
in tissues is obtained and correlated with the toxicological findings.  The question is posed whether 
immunohistochemical detection could be either an alternative or a supplementary tool in the forensic 
inquiry when the toxicological determinations are interfered with or have become impossible.  In 
particular, the brain – being an important target organ for MDMA – may be a challenging matrix for 
chromatographic extraction due to its high lipid fraction. We reported an immunohistochemical method 
for the detection of MDMA and MDA in human post-mortem brain tissues and the pituitary gland [107]. 
The detection method comprises an elaborate amplification of the original signal (antigen-antibody 
recognition; Catalyzed Signal Amplification; CSA [108]).  A distinct positive reaction was observed in all 
cortical brain regions and the neurons of the basal ganglia, the hypothalamus, the hippocampus, the 
cerebellar vermis, and the pituitary gland.  In the brainstem, relatively weak staining of neurons was seen. 
It should be noted, however, that immunohistochemical detection is restricted to the fraction bound to 
tissues, since the unbound fraction is washed out during the preparation procedure.  This is a fundamental 
difference with the toxicological quantitation in tissue homogenates, in which both the bound and the 
unbound fraction are measured. Yet, the immunohistochemical findings were in line with the toxicological 
data.  This immunohistochemical method can thus be used as evidence of intake of or even poisoning with 
MDA, MDMA and/or MDEA, and it can serve as an alternative method when the usual samples (mainly 
blood and urine) are not available for toxicological analysis (for example in polytrauma).  However, a 
drawback is that the currently available antibodies cannot distinguish the closely related amphetamine 
derivatives (MDA, MDMA and MDEA) from one another. In addition, immunodetection could possibly 
be used as a basis for further study of the distribution of these amphetamine analogues in the human body, 
and may contribute to the understanding of their neuro-biological effects.  However, as already mentioned, 
the limitation of the immunohistochemical approach is that in the brain sections, only the tissue-bound 
fraction can be demonstrated.  This constitutes a fundamental difference with the toxicological 
quantitation in tissue homogenates, in which both the bound and the unbound fractions can be assessed. 
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IV.     Discussion & conclusion 
Considering the post-mortem changes applicable to MDMA, it can be concluded that – at present 
– post-mortem degradation of MDMA is of minor consideration. However, post-mortem distribution and 
redistribution of MDMA is of major interest, in order to evaluate which fluid and/or tissue sample after 
death most closely represents the ante-mortem concentration.  To that aim, animal experimental and 
human data were closely considered and compared.  
For post-mortem toxicological analysis, whole blood MDMA concentrations are predominantly 
used.  When the corresponding serum MDMA level needs to be estimated, a conversion factor of 0.80 
would be appropriate [40].  The question arises whether an MDMA blood level can be toxic or even 
potentially lethal.  Referring to possible thanatological changes, it is not clear whether the observed post-
mortem MDMA blood level actually represents the concentration at the time of death.   However, 
referring to the distribution data of MDMA, quantification of this substance in a peripheral blood sample 
and – if the latter is impossible – quantification in a few alternative matrices such as vitreous humour or 
iliopsoas muscle can provide additional information to come to a sound conclusion.  In fact, the statement 
of Dowling can be maintained: a blood level of MDMA (or MDEA) in excess of 1.0 µg/ml has the 
potential to cause or contribute significantly toward death, whereas even levels below approximately 0.6 
µg/ml appear to be potentially consistent with a state of MDMA (or MDEA) intoxication [109]. In 
addition, individual susceptibility should be taken into account in determining whether any given dose of 
MDMA (or MDEA) can be potentially lethal [109].  On the other hand, Musshoff et al. state that MDMA 
concentrations of 0.35 – 0.5 µg/ml can be considered as toxic [110]. In Supplementary Table 1, a broad 
interval of described MDMA levels is shown and this was also substantiated by other authors, e.g. Kaye et 
al. who found in their 68 cases an interval of 0.03 – 93.0 µg/ml (mean 0.85 µg/ml) [111].  Referring to the 
reported toxicological data and as Kalant stated: it is not possible to estimate the risk and the true 
incidence of serious or fatal toxicity due to MDMA [112].  Furthermore, there is a variety of possible 
mechanisms of death [30, 113].  Or in other words, each individual MDMA-related fatality should be 
accurately considered and the medico-legal findings should be correlated with the toxicological data in 
order to come to a well-grounded conclusion. 
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